Posts Tagged ‘dutogliptin’

Positive top-line results from Phenomix’ Phase 3 trial of dutogliptin for Type 2 diabetes mellitus
Phenomix Corporation today announced positive top-line results from a six-month Phase 3 study comparing dutogliptin 400mg and 200mg once daily as monotherapy versus placebo for the treatment of patients with Type 2 diabetes mellitus. Dutogliptin is Phenomix’ internally-discovered dipeptidyl peptidase-4 (DPP-4) inhibitor.